TY - JOUR AU - Kamangar, F. AU - Dores, G. M. AU - Anderson, W. F. PY - 2006 DA - 2006// TI - Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2005.05.2308 DO - 10.1200/JCO.2005.05.2308 ID - Kamangar2006 ER - TY - JOUR AU - El-Serag, H. B. AU - Mason, A. C. PY - 1999 DA - 1999// TI - Rising incidence of hepatocellular carcinoma in the United States JO - N Engl J Med VL - 340 UR - https://doi.org/10.1056/NEJM199903113401001 DO - 10.1056/NEJM199903113401001 ID - El-Serag1999 ER - TY - JOUR AU - Sherman, M. PY - 2005 DA - 2005// TI - Hepatocellular carcinoma: epidemiology, risk factors, and screening JO - Semin Liver Dis VL - 25 UR - https://doi.org/10.1055/s-2005-871194 DO - 10.1055/s-2005-871194 ID - Sherman2005 ER - TY - JOUR AU - Thomas, M. B. AU - Zhu, A. X. PY - 2005 DA - 2005// TI - Hepatocellular carcinoma: the need for progress JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.03.196 DO - 10.1200/JCO.2005.03.196 ID - Thomas2005 ER - TY - JOUR AU - Okuda, K. PY - 1992 DA - 1992// TI - Hepatocellular carcinoma: recent progress JO - Hepatology VL - 15 UR - https://doi.org/10.1002/hep.1840150532 DO - 10.1002/hep.1840150532 ID - Okuda1992 ER - TY - JOUR AU - Sangiovanni, A. AU - Ninno, E. AU - Fasani, P. PY - 2004 DA - 2004// TI - Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance JO - Gastroenterology VL - 126 UR - https://doi.org/10.1053/j.gastro.2003.12.049 DO - 10.1053/j.gastro.2003.12.049 ID - Sangiovanni2004 ER - TY - JOUR AU - Johnson, P. J. PY - 2000 DA - 2000// TI - Systemic chemotherapy of liver tumors JO - Semin Surg Oncol VL - 19 UR - https://doi.org/3.0.CO;2-F DO - 3.0.CO;2-F ID - Johnson2000 ER - TY - JOUR AU - Llovet, J. M. AU - Sala, M. PY - 2005 DA - 2005// TI - Non-surgical therapies of hepatocellular carcinoma JO - Eur J Gastroenterol Hepatol VL - 17 UR - https://doi.org/10.1097/00042737-200505000-00006 DO - 10.1097/00042737-200505000-00006 ID - Llovet2005 ER - TY - JOUR AU - Llovet, J. M. PY - 2005 DA - 2005// TI - Updated treatment approach to hepatocellular carcinoma JO - J Gastroenterol VL - 40 UR - https://doi.org/10.1007/s00535-005-1566-3 DO - 10.1007/s00535-005-1566-3 ID - Llovet2005 ER - TY - JOUR AU - Simonetti, R. G. AU - Liberati, A. AU - Angiolini, C. PY - 1997 DA - 1997// TI - Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials JO - Ann Oncol VL - 8 UR - https://doi.org/10.1023/A:1008285123736 DO - 10.1023/A:1008285123736 ID - Simonetti1997 ER - TY - JOUR AU - Mathurin, P. AU - Rixe, O. AU - Carbonell, N. PY - 1998 DA - 1998// TI - Review article: Overview of medical treatments in unresectable hepatocellular carcinoma–an impossible meta-analysis? JO - Aliment Pharmacol Ther VL - 12 UR - https://doi.org/10.1046/j.1365-2036.1998.00286.x DO - 10.1046/j.1365-2036.1998.00286.x ID - Mathurin1998 ER - TY - JOUR AU - Yeo, W. AU - Mok, T. S. AU - Zee, B. PY - 2005 DA - 2005// TI - A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma JO - J Natl Cancer Inst VL - 97 UR - https://doi.org/10.1093/jnci/dji315 DO - 10.1093/jnci/dji315 ID - Yeo2005 ER - TY - JOUR AU - Gish, R. G. AU - Porta, C. AU - Lazar, L. PY - 2007 DA - 2007// TI - Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2006.08.4046 DO - 10.1200/JCO.2006.08.4046 ID - Gish2007 ER - TY - JOUR AU - Qin, S. AU - Bai, Y. AU - Lim, H. Y. PY - 2013 DA - 2013// TI - Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.44.5643 DO - 10.1200/JCO.2012.44.5643 ID - Qin2013 ER - TY - JOUR AU - Uray, I. P. AU - Dmitrovsky, E. AU - Brown, P. H. PY - 2016 DA - 2016// TI - Retinoids and rexinoids in cancer prevention: from laboratory to clinic JO - Semin Oncol VL - 43 UR - https://doi.org/10.1053/j.seminoncol.2015.09.002 DO - 10.1053/j.seminoncol.2015.09.002 ID - Uray2016 ER - TY - JOUR AU - Zhang, Y. AU - Guan, D. X. AU - Shi, J. PY - 2013 DA - 2013// TI - All-trans retinoic acid potentiates the chemotherapeutic effect of cisplatin by inducing differentiation of tumor initiating cells in liver cancer JO - J Hepatol VL - 59 UR - https://doi.org/10.1016/j.jhep.2013.07.009 DO - 10.1016/j.jhep.2013.07.009 ID - Zhang2013 ER - TY - JOUR AU - Guan, D. X. AU - Shi, J. AU - Zhang, Y. PY - 2015 DA - 2015// TI - Sorafenib enriches epithelial cell adhesion molecule-positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2-AKT cascade JO - Hepatology VL - 62 UR - https://doi.org/10.1002/hep.28117 DO - 10.1002/hep.28117 ID - Guan2015 ER - TY - JOUR AU - Tang, X. H. AU - Gudas, L. J. PY - 2011 DA - 2011// TI - Retinoids, retinoic acid receptors, and cancer JO - Annu Rev Pathol VL - 6 UR - https://doi.org/10.1146/annurev-pathol-011110-130303 DO - 10.1146/annurev-pathol-011110-130303 ID - Tang2011 ER - TY - JOUR AU - Luckett, T. AU - King, M. T. AU - Butow, P. N. PY - 2011 DA - 2011// TI - Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations JO - Ann Oncol VL - 22 UR - https://doi.org/10.1093/annonc/mdq721 DO - 10.1093/annonc/mdq721 ID - Luckett2011 ER - TY - JOUR AU - Smith, A. B. AU - Cocks, K. AU - Parry, D. PY - 2014 DA - 2014// TI - Reporting of health-related quality of life (HRQOL) data in oncology trials: a comparison of the European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy-General (FACT-G) JO - Qual Life Res VL - 23 UR - https://doi.org/10.1007/s11136-013-0534-2 DO - 10.1007/s11136-013-0534-2 ID - Smith2014 ER - TY - JOUR AU - Gandhi, S. AU - Khubchandani, S. AU - Iyer, R. PY - 2014 DA - 2014// TI - Quality of life and hepatocellular carcinoma JO - J Gastrointest Oncol VL - 5 UR - https://doi.org/10.3978/j.issn.2078-6891.2014.046 DO - 10.3978/j.issn.2078-6891.2014.046 ID - Gandhi2014 ER - TY - JOUR AU - Li, L. AU - Yeo, W. PY - 2017 DA - 2017// TI - Value of quality of life analysis in liver cancer: a clinician's perspective JO - World J Hepatol VL - 9 UR - https://doi.org/10.4254/wjh.v9.i20.867 DO - 10.4254/wjh.v9.i20.867 ID - Li2017 ER - TY - JOUR AU - Roxburgh, P. AU - Evans, T. R. PY - 2008 DA - 2008// TI - Systemic therapy of hepatocellular carcinoma: are we making progress? JO - Adv Ther VL - 25 UR - https://doi.org/10.1007/s12325-008-0113-z DO - 10.1007/s12325-008-0113-z ID - Roxburgh2008 ER - TY - JOUR AU - Llovet, J. M. AU - Ricci, S. AU - Mazzaferro, V. PY - 2008 DA - 2008// TI - Sorafenib in advanced hepatocellular carcinoma JO - N Engl J Med VL - 359 UR - https://doi.org/10.1056/NEJMoa0708857 DO - 10.1056/NEJMoa0708857 ID - Llovet2008 ER - TY - JOUR AU - Shiozawa, K. AU - Watanabe, M. AU - Ikehara, T. PY - 2014 DA - 2014// TI - Sustained complete response of hepatocellular carcinoma with portal vein tumor thrombus following discontinuation of sorafenib: a case report JO - Oncol Lett VL - 7 UR - https://doi.org/10.3892/ol.2013.1664 DO - 10.3892/ol.2013.1664 ID - Shiozawa2014 ER -